Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine...
Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports...
Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April 2024 Allows to continue the clinical and regulatory development of ZEPIZURE®...
Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early...
Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to ‚1 million in total, upon marketing authorizations Crossject will sell ZEPIZURE®...
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary...
Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®...
Dijon, France April 2, 2024 “ Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject's...
Crossject gender equality score reaches 96/100 in 2024
Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to ‚¬12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares,...